Infectious diseases, along with cancers, are among the main causes of death among
humans worldwide. The production of therapeutic proteins for treating diseases at large …

A variety of organisms, such as bacteria, fungi, and plants, produce secondary metabolites,
also known as natural products. Natural products have been a prolific source and an …

The production of proteins in sufficient amounts is key for their study or use as biotherapeutic
agents. Escherichia coli is the host of choice for recombinant protein production given its fast …

Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of
a broad spectrum of diseases and are increasingly used in nearly all branches of medicine …

The last few years have witnessed an unprecedented increase in the number of novel
bacterial species that hold potential to be used for metabolic engineering. Historically …

The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death
associated with substantive social, economic and societal impacts. Treatments rely on re …

Background Intraocular inflammation is an uncommon but potentially vision-threatening
adverse event related to anti-VEGF therapy. This is of increasing importance given both the …

Escherichia coli has a rich history as biology's 'rock star', driving advances across many
fields. In the wild, E. coli resides innocuously in the gut of humans and animals but is also a …

Escherichia coli is the most widely used heterologous protein expression system. However,
this system remains a challenge due to the low solubility of proteins, insufficient yield, and …

The production of recombinant proteins is one of the most significant achievements of
biotechnology in the last century. These proteins are produced in the eukaryotic or …